Laurence Reid - Nov 23, 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Director
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Nov 23, 2024
Transactions value $
$0
Form type
4
Date filed
11/26/2024, 04:41 PM
Previous filing
Sep 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Stock Option (Right to Buy) Award $0 +17K $0.00 17K Nov 23, 2024 Common Stock 17K $10.07 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date.